GlobeStar Therapeutics Corp Annual Operating Income (Loss) in USD from 2011 to 2023

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: GlobeStar Therapeutics Corp quarterly/annual Operating Income (Loss) history and growth rate from 2011 to 2023.
GlobeStar Therapeutics Corp Operating Income (Loss) for the quarter ending June 30, 2024 was -$193K, a 84.9% increase year-over-year.
GlobeStar Therapeutics Corp Operating Income (Loss) for the twelve months ending June 30, 2024 was -$805K, a 57.1% increase year-over-year.
GlobeStar Therapeutics Corp annual Operating Income (Loss) for 2023 was -$1.86M, a 47.4% decline from 2022.
GlobeStar Therapeutics Corp annual Operating Income (Loss) for 2022 was -$1.27M, a 86.1% increase from 2021.
GlobeStar Therapeutics Corp annual Operating Income (Loss) for 2021 was -$9.09M, a 2895% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Annual (USD)

Operating Income (Loss), YoY Annual Growth (%)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2023	-$1.86M	-$599K	-47.4%	Oct 1, 2022	Sep 30, 2023	10-K	2024-01-19
2022	-$1.27M	+$7.83M	+86.1%	Oct 1, 2021	Sep 30, 2022	10-K	2024-01-19
2021	-$9.09M	-$8.79M	-2895%	Oct 1, 2020	Sep 30, 2021	10-K	2023-01-09
2020	-$304K	+$12.2K	+3.86%	Oct 1, 2019	Sep 30, 2020	10-K	2022-01-05
2019	-$316K	+$35.2K	+10%	Oct 1, 2018	Sep 30, 2019	10-K	2020-12-03
2018	-$351K	+$110K	+23.8%	Oct 1, 2017	Sep 30, 2018	10-K	2019-12-31
2017	-$461K			Oct 1, 2016	Sep 30, 2017	10-K	2019-01-03
2015	-$698K	-$240K	-52.5%	Oct 1, 2014	Sep 30, 2015	10-K/A	2016-01-22
2014	-$458K	+$188K	+29.1%	Oct 1, 2013	Sep 30, 2014	10-K/A	2016-01-22
2013	-$645K	+$300K	+31.7%	Oct 1, 2012	Sep 30, 2013	10-K/A	2015-01-27
2012	-$945K	-$891K	-1647%	Oct 1, 2011	Sep 30, 2012	10-K/A	2014-01-23
2011	-$54.1K			Oct 1, 2010	Sep 30, 2011	10-K/A	2013-03-07

Showing 1 to 12 of 12 entries

* An asterisk sign (*) next to the value indicates that the value is likely invalid.